Boston, MA

Day One
Wednesday, October 18, 2017

Day Two
Thursday, October 19, 2017

Breakfast & Networking

Chairs’ Opening Remarks

Plenary Address: Dissecting the Progression from Predictive Biomarker Signature to Companion Diagnostic to Commercial Launch and Adoption

Collaborations and Technologies to Deliver Precision Medicine

  • Sarah Hersey Companion Diagnostics & Precision Medicine Head, Celgene


  • Evaluating pre-competitive collaborations: How do we ensure we are winning for our patients?
  • Discussing the evolution of diagnostic testing in the precision medicine field
  • Analyzing strategies for standardization of diagnostic testing

Key Trends in CDx Development for Precision Medicine Success

  • Jason Simon Scientific Director, Oncology Diagnostics, Janssen R&D


  • Why, when and how should you decide to translate your biomarker strategy into a high value CDx approach
  • Discussing how assay platforms can evolve to better inform patient selection to provide more meaningful insights into outcomes?
  • Evaluating the value of complementary diagnostics in validating “continuum” signatures to guide therapy
  • Discussing how assay platforms can evolve to better inform patient selection to provide more meaningful insights into outcomes?
  • Understanding how to build a companion diagnostic program into your therapeutic development without compromising timeline goals

Successful Development of an NGS-Based Companion Diagnostic Test to Support Multiple NSCLC Drug Therapies

  • Jim Godsey Vice President, R&D, Clinical Sequencing Division, Thermo Fisher Scientific


  • Challenging considerations
  • Lessons learned from the successes
  • Insight and an assessment into future directions

Mitigating Risk when Navigating the Journey from Clinical Trial Assay Validation to the Commercial Deployment of a Companion Diagnostic

  • Dan Snyder President & Chief Executive Officer, Molecular MD


  • Delivering insight into how to smooth the transition of assay development from proof of concept to registrational clinical trial to regulatory approval by identifying the true diagnostic need and developing an assay that is more suitable for each phase of the lifecycle that avoids multiple bridging studies
  • Developing a framework for commercial/market considerations to help pharma avoid making poor decisions which can delay uptake after launch
  • From CTA validation and IDE strategies to commercial CDx implementation, insights and examples will be provided on how to effectively manage a co-development project with ever compressing timelines

Accelerating The Adoption of Companion Diagnostics

  • Jason DeLoach International Product Manager, CDx, Ventana Companion Diagnostics


  • Discussing key checkpoints to ensure drug and diagnostic are streamlined for commercial success post launch
  • Driving awareness of companion diagnostics commercially to advance the uptake and adoption of both drug and diagnostic

Morning Refreshments & Networking

Advancing the Development & Clinical Utility of Liquid Biopsies

11.30 Proving the Clinical Utility of ctDNA

  • Advancing the practical applications of ctDNA for patient selection, monitoring and therapeutic recommendations
  • Validating the impact of ctDNA testing on the accuracy of clinical decision: What’s real, what’s technical, what’s just tumor heterogeneity?
  • Harnessing ctDNA to identify responder population by their tumour burden

Daniel Stetson, Associate Principal Scientist, Astrazeneca

12.00 The OncoBEAM™ Platform: Global Implementation of a Highly Sensitive Liquid Biopsy Technology for Clinical Trials and Clinical Practice

  • The OncoBEAM™ Platform has been validated across cancer types with sensitivity of around 0.02% MF
  • Sensitivity matters in liquid biopsies for accurate biomarker detection and patient classification
  • Sysmex Inostics OncoBEAM™ assays are available for CRO services and/or Patient testing globally

Dan Edelstein, Director, Clinical Marketing & New Technology, Sysmex Inostics

12.30 Deep Sequencing QC: A Component Study of the FDA-led Sequencing Quality Control Project Phase 2 (SEQC2)

  • Comprehensive QC assessments of reproducibility and detection sensitivity are essential in translating deep targeted DNA sequencing from lab development to clinical application
  • A set of benchmarking samples is designed to empower a cross-lab evaluation of about a dozen pan-cancer panels and liquid biopsy kits
  • Quality metrics will be developed to inform the confidence of each mutation call

Joshua Xu, Principal Investigator, National Center for Toxicological Research (NCTR), FDA

13.00 Improved Sensitivity for EGFR Mutation Profiles in Liquid Biopsies Using the VTX-1 Liquid Biopsy System

  • Discussing VTX-1, a simple, fully automated system that uses the physical properties of CTCs to isolate them directly from whole blood
  • Demonstrating a workflow for the collection and EGFR mutation analysis of both cfDNA and CTCs from a single blood tube using the VTX-1 platform, and will
  • Case study: Comparing the results to matched tumor samples for NSCLC patients

Elodie Sollier, Chief Scientific Officer, Vortex Biosciences

13.10 Close of Stream

13.20 Networking Lunch

Bridging Validation to Real-World Application

11.30 Panel Discussion: The Real World Application and Adoption of Drug and Dx and the Impact on What Platform to Choose and Why

  • Selecting the right assay for your biomarker to promote physician adoption
  • Discussing different assay merits on cost, turn around time, assay sensitivity, labor resources on selecting the appropriate assay to maximize chance of adoption
  • With such rapid advancement in molecular diagnostics how do we ensure commercialized and adopted tests don’t become obsolete?
  • Debating IP, propriatary assays and the impact of platform standardization
  • How to improve the commercial launch of drug-dx products to gain early buy-in and adoption
  • Debating the prevalence of the biomarker and the transition from what is relevant in the clinical trial setting with what is viable in the real world
  • Discussing the health economics around CDx deployment and acceptance to improve adoption of the diagnostic test
  • A stark look at the post market real world: How is the diagnostic impact adoption and market penetration for my precision medicine?
  • Are we progressing the IVD vs LDT debate and how is the current situation impacting on the real world adoption of diagnostics?

Jason Simon,  Scientific Director, Oncology Diagnostics, Janssen R&D

Ferran Prat, Vice President, Strategic Industry Ventures, MD Anderson Cancer Center

Sarah Hersey, Companion Diagnostics & Precision Medicine Head, Celgene

12.30 Validation of NGS Workflows for Precision Medicine

  • Discussing best practice clinical guidelines for the validation of NGS pipelines in a personalised medicine context to support the increasing complexity of biomarkers in precision genomics, NGS-based patient stratification for therapy and/or clinical trials
  • Validating NGS pipeline depends upon processes for calibrating and implementing quality thresholds for NGS data files as well as for optimising accuracy by maximising sensitivity without losing specificity
  • Analyzing  the importance of NGS data validation together with data interpretation for actionable clinical outcome

Christophe Roos, Chief Scientific Officer, Euformatics, speaking on behalf of Horizon Discovery

13.00 Using Computational Tissue Analysis to Deliver Clinical Response Profiles for Diagnostic Approaches

  • Using image analysis of IHC stained tissues to create a response profile from clinical outcome data.
  • Determining what computational scores are relevant to the biological mechanism.
  • Delivering tissue image analysis based patient selection tools in a regulated clinical setting to support drug development and commercialization

Joseph Krueger, Chief Scientific Officer, Flagship Biosciences

13.10 Autoimmune Dysfunction as a Mechanism in Neuropsychiatric Disorders

  • Neuropsychiatric disorders contribute the greatest burden on society and eclipse cancer and heart disease, not to mention causing distress and disability to the individual and their family
  • Traditional therapeutic intervention is symptomatic treatment with psychotropic drugs
  • Growing clinical and scientific evidence is pointing to the immune system and inflammation as a potential etiology and target for intervention
  • Evidence for new therapeutic targets will be presented

Craig Shimasaki, President & CEO, Moleculera Labs

13.20 Networking Lunch

Investigating Avenues for Empowering Precision Medicine Success: Analytical Capabilities & the Microbiome

14.20 Harnessing Statistical Analysis to Prove Clinical Validation and Relevance to Decision Making

  • Delineating statistical significance and biological significance: What is enough statistical significance to drive a meaningful change in a patient population?
  • Analytical strategies for robustly delineating beyond “biomarker positive” to enrich for “responder positive populations”
  • Realizing the power of translational bioinformatics and interpretive methods to optimize the transformation of data analysis into proactive measure of health outcomes

Matthew Onsum, Director & Head of Bioinformatics, Seattle Genetics

14.50 Building and Implementing Genomic Capabilities for Clinical Studies

  • Understanding how to build and integrate an analytical framework to implement advanced analytic strategies
  • Pre-selecting non-responsive patients to simultaneously better set up clinical trials for success and identify unmet medical need for new, innovation personalized treatment
  • Defining cut offs for patient selection: Criteria for defining cutoffs, protocols of robust validation and downstream impact on clinical success

Sunita Badola, Director, Functional Genomics, Takeda

15:20 Evaluating the Role of Microbiome Diagnostics in Precision Medicine

  • Overcoming wide variation in microbiome sequencing and analysis to establish standards and enhance the prospect of clinically useful microbiome based signatures
  • Evaluating standardization methods and bioinformatics approaches for interrogating microbiome based signatures
  • Understanding the impact of the microbiome on drug metabolism and sensitivity and the potential for harnessing the microbiota for personalized therapeutics

Rodolphe Clerval, Chief Business Officer, Enterome Bioscience

Clinical Biomarkers Afternoon Networking Session


Join us after the end of our educational program for an informal networking event. Make those final connections, wrap up your business conversations and become a central part of our Clinical Biomarker family.

World CDx & Clinical Biomarkers Closing Refreshments

Close of Day Two & End of 8th Annual World CDx & Clinical Biomarkers